Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region

<p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We con...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Laupland Kevin B [verfasserIn] Church Deirdre L [verfasserIn] Ross Terry [verfasserIn] Pitout Johann DD [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2006

Übergeordnetes Werk:	In: Annals of Clinical Microbiology and Antimicrobials - BMC, 2003, 5(2006), 1, p 12
Übergeordnetes Werk:	volume:5 ; year:2006 ; number:1, p 12

Links:	Link aufrufen Link aufrufen Link aufrufen Journal toc

DOI / URN:	10.1186/1476-0711-5-12

Katalog-ID:	DOAJ06608234X

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ06608234X
003	DE-627
005	20230309054842.0
007	cr uuu---uuuuu
008	230228s2006 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/1476-0711-5-12 \|2 doi
035			\|a (DE-627)DOAJ06608234X
035			\|a (DE-599)DOAJ662b7561d6244e17b95e7daca823b625
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RM1-950
050		0	\|a RC109-216
050		0	\|a QR1-502
100	0		\|a Laupland Kevin B \|e verfasserin \|4 aut
245	1	0	\|a Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
264		1	\|c 2006
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<
653		0	\|a Therapeutics. Pharmacology
653		0	\|a Infectious and parasitic diseases
653		0	\|a Microbiology
700	0		\|a Church Deirdre L \|e verfasserin \|4 aut
700	0		\|a Ross Terry \|e verfasserin \|4 aut
700	0		\|a Pitout Johann DD \|e verfasserin \|4 aut
773	0	8	\|i In \|t Annals of Clinical Microbiology and Antimicrobials \|d BMC, 2003 \|g 5(2006), 1, p 12 \|w (DE-627)359783430 \|w (DE-600)2097873-X \|x 14760711 \|7 nnns
773	1	8	\|g volume:5 \|g year:2006 \|g number:1, p 12
856	4	0	\|u https://doi.org/10.1186/1476-0711-5-12 \|z kostenfrei
856	4	0	\|u https://doaj.org/article/662b7561d6244e17b95e7daca823b625 \|z kostenfrei
856	4	0	\|u http://www.ann-clinmicrob.com/content/5/1/12 \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/1476-0711 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 5 \|j 2006 \|e 1, p 12

Indexfelder

author_variant	l k b lkb c d l cdl r t rt p j d pjd
matchkey_str	article:14760711:2006----::ouainaelbrtrsrelacoihfiavitsltsnl
hierarchy_sort_str	2006
callnumber-subject-code	RM
publishDate	2006
allfields	10.1186/1476-0711-5-12 doi (DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Laupland Kevin B verfasserin aut Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p< Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Church Deirdre L verfasserin aut Ross Terry verfasserin aut Pitout Johann DD verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 5(2006), 1, p 12 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:5 year:2006 number:1, p 12 https://doi.org/10.1186/1476-0711-5-12 kostenfrei https://doaj.org/article/662b7561d6244e17b95e7daca823b625 kostenfrei http://www.ann-clinmicrob.com/content/5/1/12 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2006 1, p 12
spelling	10.1186/1476-0711-5-12 doi (DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Laupland Kevin B verfasserin aut Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p< Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Church Deirdre L verfasserin aut Ross Terry verfasserin aut Pitout Johann DD verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 5(2006), 1, p 12 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:5 year:2006 number:1, p 12 https://doi.org/10.1186/1476-0711-5-12 kostenfrei https://doaj.org/article/662b7561d6244e17b95e7daca823b625 kostenfrei http://www.ann-clinmicrob.com/content/5/1/12 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2006 1, p 12
allfields_unstemmed	10.1186/1476-0711-5-12 doi (DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Laupland Kevin B verfasserin aut Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p< Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Church Deirdre L verfasserin aut Ross Terry verfasserin aut Pitout Johann DD verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 5(2006), 1, p 12 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:5 year:2006 number:1, p 12 https://doi.org/10.1186/1476-0711-5-12 kostenfrei https://doaj.org/article/662b7561d6244e17b95e7daca823b625 kostenfrei http://www.ann-clinmicrob.com/content/5/1/12 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2006 1, p 12
allfieldsGer	10.1186/1476-0711-5-12 doi (DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Laupland Kevin B verfasserin aut Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p< Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Church Deirdre L verfasserin aut Ross Terry verfasserin aut Pitout Johann DD verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 5(2006), 1, p 12 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:5 year:2006 number:1, p 12 https://doi.org/10.1186/1476-0711-5-12 kostenfrei https://doaj.org/article/662b7561d6244e17b95e7daca823b625 kostenfrei http://www.ann-clinmicrob.com/content/5/1/12 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2006 1, p 12
allfieldsSound	10.1186/1476-0711-5-12 doi (DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625 DE-627 ger DE-627 rakwb eng RM1-950 RC109-216 QR1-502 Laupland Kevin B verfasserin aut Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier <p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p< Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology Church Deirdre L verfasserin aut Ross Terry verfasserin aut Pitout Johann DD verfasserin aut In Annals of Clinical Microbiology and Antimicrobials BMC, 2003 5(2006), 1, p 12 (DE-627)359783430 (DE-600)2097873-X 14760711 nnns volume:5 year:2006 number:1, p 12 https://doi.org/10.1186/1476-0711-5-12 kostenfrei https://doaj.org/article/662b7561d6244e17b95e7daca823b625 kostenfrei http://www.ann-clinmicrob.com/content/5/1/12 kostenfrei https://doaj.org/toc/1476-0711 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 5 2006 1, p 12
language	English
source	In Annals of Clinical Microbiology and Antimicrobials 5(2006), 1, p 12 volume:5 year:2006 number:1, p 12
sourceStr	In Annals of Clinical Microbiology and Antimicrobials 5(2006), 1, p 12 volume:5 year:2006 number:1, p 12
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Therapeutics. Pharmacology Infectious and parasitic diseases Microbiology
isfreeaccess_bool	true
container_title	Annals of Clinical Microbiology and Antimicrobials
authorswithroles_txt_mv	Laupland Kevin B @@aut@@ Church Deirdre L @@aut@@ Ross Terry @@aut@@ Pitout Johann DD @@aut@@
publishDateDaySort_date	2006-01-01T00:00:00Z
hierarchy_top_id	359783430
id	DOAJ06608234X
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06608234X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309054842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2006 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-0711-5-12</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06608234X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ662b7561d6244e17b95e7daca823b625</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Laupland Kevin B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Church Deirdre L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ross Terry</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pitout Johann DD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Annals of Clinical Microbiology and Antimicrobials</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">5(2006), 1, p 12</subfield><subfield code="w">(DE-627)359783430</subfield><subfield code="w">(DE-600)2097873-X</subfield><subfield code="x">14760711</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:1, p 12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1476-0711-5-12</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/662b7561d6244e17b95e7daca823b625</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ann-clinmicrob.com/content/5/1/12</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1476-0711</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2006</subfield><subfield code="e">1, p 12</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Laupland Kevin B
spellingShingle	Laupland Kevin B misc RM1-950 misc RC109-216 misc QR1-502 misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
authorStr	Laupland Kevin B
ppnlink_with_tag_str_mv	@@773@@(DE-627)359783430
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RM1-950
illustrated	Not Illustrated
issn	14760711
topic_title	RM1-950 RC109-216 QR1-502 Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
topic	misc RM1-950 misc RC109-216 misc QR1-502 misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology
topic_unstemmed	misc RM1-950 misc RC109-216 misc QR1-502 misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology
topic_browse	misc RM1-950 misc RC109-216 misc QR1-502 misc Therapeutics. Pharmacology misc Infectious and parasitic diseases misc Microbiology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Annals of Clinical Microbiology and Antimicrobials
hierarchy_parent_id	359783430
hierarchy_top_title	Annals of Clinical Microbiology and Antimicrobials
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)359783430 (DE-600)2097873-X
title	Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
ctrlnum	(DE-627)DOAJ06608234X (DE-599)DOAJ662b7561d6244e17b95e7daca823b625
title_full	Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
author_sort	Laupland Kevin B
journal	Annals of Clinical Microbiology and Antimicrobials
journalStr	Annals of Clinical Microbiology and Antimicrobials
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2006
contenttype_str_mv	txt
author_browse	Laupland Kevin B Church Deirdre L Ross Terry Pitout Johann DD
container_volume	5
class	RM1-950 RC109-216 QR1-502
format_se	Elektronische Aufsätze
author-letter	Laupland Kevin B
doi_str_mv	10.1186/1476-0711-5-12
author2-role	verfasserin
title_sort	population-based laboratory surveillance of <it<hafnia alvei </it<isolates in a large canadian health region
callnumber	RM1-950
title_auth	Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
abstract	<p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<
abstractGer	<p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<
abstract_unstemmed	<p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_11 GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_70 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2003 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1, p 12
title_short	Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region
url	https://doi.org/10.1186/1476-0711-5-12 https://doaj.org/article/662b7561d6244e17b95e7daca823b625 http://www.ann-clinmicrob.com/content/5/1/12 https://doaj.org/toc/1476-0711
remote_bool	true
author2	Church Deirdre L Ross Terry Pitout Johann DD
author2Str	Church Deirdre L Ross Terry Pitout Johann DD
ppnlink	359783430
callnumber-subject	RM - Therapeutics and Pharmacology
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
doi_str	10.1186/1476-0711-5-12
callnumber-a	RM1-950
up_date	2024-07-03T18:08:34.026Z
_version_	1803582296942444544
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ06608234X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309054842.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2006 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/1476-0711-5-12</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ06608234X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ662b7561d6244e17b95e7daca823b625</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RM1-950</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC109-216</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QR1-502</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Laupland Kevin B</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a"><p<Abstract</p< <p<Background</p< <p<Hospital-based series have characterized <it<Hafnia alvei </it<primarily as an infrequent agent of polymicrobial nosocomial infections in males with underlying illness.</p< <p<Methods</p< <p<We conducted population-based laboratory surveillance in the Calgary Health Region during 2000–2005 to define the incidence, demographic risk factors for acquisition, and anti-microbial susceptibilities of <it<Hafnia alvei </it<isolates.</p< <p<Results</p< <p<A total of 138 patients with <it<Hafnia alvei </it<isolates were identified (2.1/100,000/year) and two-thirds were of community onset. Older age and female gender were important risk factors for acquisition. The most common focus of isolation was urine in 112 (81%), followed by lower respiratory tract in 10 (7%), and soft tissue in 5 (4%), and the majority (94; 68%) were mono-microbial. Most isolates were resistant to ampicillin (111;80%), cephalothin (106; 77%), amoxicillin/clavulanate (98; 71%), and cefazolin (95; 69%) but none to imipenem or ciprofloxacin.</p< <p<Conclusion</p< <p<<it<Hafnia alvei </it<was most commonly isolated as a mono-microbial etiology from the urinary tract in women from the community. This study highlights the importance of population-based studies in accurately defining the epidemiology of an infectious disease.</p<</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Therapeutics. Pharmacology</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Infectious and parasitic diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Microbiology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Church Deirdre L</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ross Terry</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Pitout Johann DD</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Annals of Clinical Microbiology and Antimicrobials</subfield><subfield code="d">BMC, 2003</subfield><subfield code="g">5(2006), 1, p 12</subfield><subfield code="w">(DE-627)359783430</subfield><subfield code="w">(DE-600)2097873-X</subfield><subfield code="x">14760711</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:5</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:1, p 12</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1186/1476-0711-5-12</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/662b7561d6244e17b95e7daca823b625</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.ann-clinmicrob.com/content/5/1/12</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1476-0711</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2003</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">5</subfield><subfield code="j">2006</subfield><subfield code="e">1, p 12</subfield></datafield></record></collection>
score	7.399618

Nicht das Richtige dabei?

Schreiben Sie uns!

Population-based laboratory surveillance of <it<Hafnia alvei </it<isolates in a large Canadian health region

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?